AUTHORS
Michael A Pratta, MS, Isac Lee, PhD2, Shuyuan Lou, PhD3, Britnie Thomas, PhD4, Valkal Bhatt, PharmD5, Peter Ordentlich, PhD6, Ian M. Catlett, PhD7
AFFILIATIONS
1 Incyte Corporation, Wilmington, Delaware, United States
2 Incyte Corporation, Wilmington, Delaware, United States
3 Incyte Corporation, Wilmington, Delaware, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 Incyte Corporation, Wilmington, Delaware, United States
6 Syndax Pharmaceuticals, Inc., New York, New York, United States
7 Incyte Corporation, Wilmington, Delaware, United States
ABSTRACT
Introduction: Chronic graft-versus-host disease (cGVHD) presents with multisystem organ involvement and broad symptomology. Although clinical staging and grading of cGVHD manifestations are defined, systemic biomarkers that reflect tissue-specific disease severity or early clinical improvement need further investigation. Treatment with axatilimab (AXA), a high-affinity monoclonal antibody targeting colony-stimulating factor 1 receptor (CSF-1R), depletes CSF-1R–dependent monocytes and macrophages that potentiate inflammation and fibrosis in patients with cGVHD. In the pivotal AGAVE-201 trial (NCT04710576), an overall response (95% CI) in the first 6 cycles occurred in 74% (63%–83%) of patients in the AXA 0.3 mg/kg every 2 weeks (Q2W) cohort, and AXA was generally well tolerated. Overall response to AXA in AGAVE-201 was associated with significant depletion of CSF-1R⁺ macrophages and increases in regulatory T cells in skin. Identification of additional biomarkers that predict treatment responses in patients with cGVHD would support clinical decision-making.
Aims: Circulating proteomic profiles were investigated for their association with baseline organ severity and early on-treatment clinical changes in patients with cGVHD receiving AXA.
Methods: This proteomic analysis assessed serum proteins to identify potential biomarkers associated with cGVHD severity and early treatment response in AGAVE-201. AGAVE-201 enrolled a total of 241 patients (0.3 mg/kg Q2W, n=80; 1 mg/kg Q2W, n=81; 3 mg/kg every 4 weeks, n=80). The primary endpoint was overall response rate in the first 6 treatment cycles per 2014 National Institutes of Health (NIH) consensus criteria. Serum was collected at baseline (Cycle [C] 1 Day [D] 1), C1D8, and C2D1 (after approximately 4 weeks of treatment). Broad proteomic analysis was performed using OLINK Explore HT, which measures >5000 proteins. Differentially expressed proteins (DEPs) were based on fold change >1.5 from baseline (C1D1) and false discovery rate (FDR)-adjusted P value <0.05. Clinical NIH severity scores for patients across all doses with 11 organs/features, including skin (n=171), joints/fascia (n=145), mouth (n=95), lungs (n=93), and liver (n=34), were derived from Study Data Tabulation Model domains. Analyses focused on protein levels at baseline (C1D1) and early on-treatment (C2D1) samples, which showed the most robust change, from 209 proteomics-evaluable patients matched to clinical scores, both at C2D1 and best overall response, using limma moderated linear models performed per organ with pooled doses at baseline.
Results: Baseline circulating protein signatures correlated with organ severity, with the strongest signals observed for skin and lungs. At baseline, FDR-significant associations were identified for skin (35 proteins), lungs (42), joints/fascia (13), and mouth (2), whereas liver analyses were limited by lack of a quantitative score. Skin-associated proteins were enriched for fibrosis and extracellular matrix (ECM) biology (eg, COMP, CCN1/2, ACTA2, LTBP2, SERPINE1, and SMOC2), with pathway enrichment for epithelial-mesenchymal transition, wound healing, ECM proteoglycans, and TGF- signaling. Lung-associated concordant proteins highlighted an inflammatory signature including epithelial markers (eg, MUC16 and CEACAM6) and immune or myeloid-associated proteins (eg, CD86, CD302, PF4/CXCL4, PDCD1, and LY9). Lung-associated proteins were also enriched for allograft rejection, cytokine production, and immune system pathways. Selected baseline severity markers, such as ACTA2 for skin and MUC16 for lungs, showed directional decreases at C2D1 with treatment responses, suggesting a correlation between baseline biological drivers of clinical severity and changes as a response to AXA treatment.
Conclusion: Although statistical analyses were restricted by high variability of protein expression and the limited number of patients with disease manifestations and early improvement in some organs, systemic proteomics identified robust baseline biomarkers of tissue-specific cGVHD severity, particularly for skin and lungs. These data also provide early evidence to support skin- and lung-specific response biomarkers, such as ACTA2 for skin and MUC16 for lungs, that may predict organ-specific responses in patients with cGVHD. These findings support circulating fibrosis-related and inflammatory protein signatures as markers of organ involvement and their correlation with clinical improvement with AXA.
DISCLOSURES
Isac Lee, PhD: Incyte Corporation - Stock (publicly traded); Incyte Corporation - Current Employment